FDA warned Verde Cosmetic Labs after an inspection found inadequate CGMP controls for OTC topical drugs, including cleaning and water system failures.
What happened
FDA inspected Verde Cosmetic Labs in Northridge, California, from September 27 to October 15, 2021. The agency found significant CGMP violations for OTC topical drugs such as sunscreens, pain-relief products, and acne treatments, including failures in quality unit oversight, process validation, cleaning validation, and purified-water monitoring. FDA also found out-of-specification water results that were not investigated.
What FDA found
The quality unit did not ensure microbiological testing before release, proper investigations, change control, stability testing, and annual product reviews.
21 CFR 211.22The company lacked adequate process validation and equipment qualification for its drug products and filling lines.
21 CFR 211.100(a)Cleaning procedures and validation were inadequate to prevent cross-contamination between drug and cosmetic products on shared filling lines.
21 CFR 211.67(b)The company did not follow its purified-water procedures; it missed sampling and sanitization and did not investigate out-of-specification water results.
21 CFR 211.160(a)
What FDA wants
FDA asks the company to correct the violations promptly and respond in writing within 15 working days with corrective actions, assessments, and remediation plans. If it cannot complete the actions in that time, it must explain the delay and give a schedule.
Who should pay attention
- brands and retailers that buy OTC topical drugs from contract manufacturers
- contract manufacturers sharing filling lines between drugs and cosmetics
- quality and regulatory teams overseeing OTC drug suppliers
This is a summary. Read the original letter on fda.gov.